Home › Brands › Cresco Labs
⚐ Flag an error How this page was made
Also known as: Cresco Labs Inc. · CL (CSE ticker) · CRLBF (OTC ticker)

Cresco Labs

Multi-state cannabis operator with cultivation, retail, and branded product lines across regulated US markets.

Automated fact-check pass
7 cited sources
Published
Last reviewed
How this page was made
↯ The honest take

Cresco is one of the larger US cannabis operators, but size claims in cannabis media rely on self-reported revenue and unaudited trade rankings. The company is real, publicly traded, and operates across multiple states—but individual state licenses, product availability, and regulatory status change frequently. Always verify current license status with your state regulator before assuming a product is available or that a Sunnyside store is operating near you.

What it is

Cresco Labs Inc. is a US multi-state cannabis operator (MSO) headquartered in Chicago, Illinois [1]. It was co-founded in 2013 by Charles Bachtell and Joe Caltabiano and went public on the Canadian Securities Exchange in December 2018 through a reverse takeover [2]. The company operates across cultivation, manufacturing, branded packaged goods, and retail, and is organized as a vertically integrated cannabis company under state licenses [1].

Cresko is dual-listed on the Canadian Securities Exchange (CL) and trades over-the-counter in the US (CRLBF). Like other plant-touching MSOs, it cannot list on a major US exchange under current federal cannabis prohibition [3]. Strong evidence

Ownership and structure

Cresco Labs is publicly traded with no parent company. Ownership is distributed across institutional and retail shareholders; insiders and founders hold equity disclosed in continuous disclosure filings on SEDAR+ [1]. Charles Bachtell serves as CEO; the executive team and board are listed in the company's annual reports [1].

The corporate structure uses an Up-C / multi-class share arrangement common to US cannabis issuers on the CSE, which separates economic and voting interests across subordinate, proportionate, and super-voting shares [1]. This structure is standard in the industry to navigate US federal cannabis prohibition. Readers evaluating the company financially should consult the most recent annual report and MD&A on SEDAR+ directly rather than relying on third-party summaries [1].

Market and operations

Cresco operates in a subset of US state-legal cannabis markets. The company has held licenses or operated in states including Illinois, Pennsylvania, Ohio, Massachusetts, New York, Florida, Michigan, and others, though the exact footprint has shifted as Cresco has divested assets in response to market and capital conditions [1][4]. State license status changes frequently—always verify with the relevant state cannabis regulator before assuming a Cresco-branded product or Sunnyside store is currently operating in a given market.

Category focus spans flower, pre-rolls, vapes, concentrates, edibles, and tinctures, distributed both into third-party dispensaries and through Cresco's own Sunnyside retail chain [1]. The company disclosed that in Illinois, where it is headquartered, it held multiple retail and cultivation licenses as of its most recent regulatory filings [1].

Brands and products

Cresco's branded product lines, as listed in company disclosures, include [1]:

Retail operates under the Sunnyside banner [1]. Inclusion of a brand in this list is descriptive, not an endorsement; product quality, terpene profiles, and potency vary by batch and by state, since each state's production is licensed separately and cannot legally cross state lines under federal law [3].

Reputation and controversies

Cresco has been recognized in cannabis trade media rankings (e.g., MJBizDaily, Green Market Report) as one of the larger US MSOs by reported revenue [4]. Weak / limited Such rankings are not independently audited and depend heavily on self-reported data from operators; readers should verify claims of market position by checking the company's own regulatory filings rather than relying on trade-press summaries.

The most consequential recent event was the failed acquisition of Columbia Care. Announced in March 2022 as a roughly US$2 billion all-stock deal that would have created the largest US MSO by revenue, the transaction was mutually terminated in July 2023, with both companies citing changes in the capital markets and regulatory environment [5][6]. Following the termination, Cresco undertook layoffs and divested or wound down operations in several states [4][6].

As with all large MSOs operating across multiple state jurisdictions, Cresco has been subject to the routine regulatory inspections, product recalls, and compliance actions that occur across a multi-state footprint. Readers should search the relevant state cannabis regulator's recall and enforcement database for current, specific items rather than relying on a static summary.

Cresco-branded products and Sunnyside dispensaries operate only in US states where cannabis is legal under state law and where Cresco holds the relevant licenses. Cannabis remains a Schedule I substance under US federal law, and no Cresco product may legally cross state lines [3]. Strong evidence A 'Cresco' product manufactured in Illinois and a 'Cresco' product manufactured in Pennsylvania are produced under separate state licenses and are not the same physical supply chain, even when packaging looks identical.

The DEA's August 2023 recommendation to reschedule cannabis to Schedule III, and subsequent rulemaking, could materially change the regulatory and business landscape for operators like Cresco [7]. As of October 2026, this rescheduling had not been finalized into federal law.

What to verify before relying on brand claims

Before relying on any Cresco marketing, retailer claim, or third-party summary:

  1. License status. Confirm Cresco/Sunnyside is currently licensed in your state via the state cannabis regulator's public license lookup. License status changes and is not reflected in real-time on company websites.
  2. Product COA. For any specific SKU, request or look up the certificate of analysis (lab report). Potency and contaminant testing are state-mandated, but testing labs and methodologies vary by state [3].
  3. Recalls. Check the state regulator's recall notices for the production batch code on your label.
  4. Financial claims. For 'largest,' 'top,' or 'number-one' claims, check Cresco's most recent annual filing on SEDAR+ rather than press releases [1].
  5. Ownership of retail. Not every Sunnyside-branded dispensary is wholly owned by Cresco in every market; licensed entities can differ from the consumer-facing brand.

Profile last verified: October 2026

Sources

  1. Government Cresco Labs Inc. Annual reports, continuous disclosure documents, and regulatory filings. SEDAR+ (Canadian securities regulators).
  2. Reported Schroyer, J. (2018). 'Cresco Labs completes reverse takeover, begins trading on CSE.' Marijuana Business Daily, December 2018.
  3. Government U.S. Drug Enforcement Administration. Drug Scheduling, Schedule I substances, and federal cannabis prohibition.
  4. Reported Marijuana Business Daily. Ongoing coverage of US multi-state operator rankings, operational updates, and divestiture announcements, 2022–2024.
  5. Reported Reuters / Bloomberg. 'Cresco Labs to acquire Columbia Care in $2 billion all-stock deal.' March 2022.
  6. Reported Schroyer, J. (2023). 'Cresco Labs, Columbia Care call off $2 billion merger.' Marijuana Business Daily, July 31, 2023.
  7. Government U.S. Department of Health and Human Services / DEA. Marijuana rescheduling proposed rule and HHS recommendation, Federal Register, May 21, 2024.

How this page was made

Generation history

Oct 31, 2026
Fact-check pass — raised 4 flags
Oct 31, 2026
Revision
Jun 8, 2026
Fact-check pass — raised 2 flags
Jun 8, 2026
Initial draft

Drafted with AI assistance and checked by a separate automated fact-check pass. Not every article has been read by a person. See how articles are made.